ATTO
Atento SA
NASDAQ · Healthcare · Biotechnology · US
$15.27
−3.35%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- —
- EBIT
- —
- EPS
- —
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- +0.0%
- EBITDA
- +6.7%
- EPS
- +3.3%
Three-year CAGR
- Revenue
- —
- EBITDA
- -60.9%
- EBIT
- -61.6%
- Net income
- -52.3%
- EPS
- -35.2%
- Free cash flow
- -67.1%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026